Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pediatric Reviews
  4. Volume 21, Issue 2
  5. Article
Volume 21, Issue 2
  • ISSN: 1573-3963
  • E-ISSN: 1875-6336

Abstract

Background

Neuroblastoma is the most com mon extra-cranial solid tu mor in children. The survival rate of relapsed/refractory neuroblastoma is dismal. Late recurrence may occur rarely.

Case Presentation

We have, herein, presented a case with stage IV neuroblastoma who relapsed after 11 years and had a subsequent relapse after 15 years from the initial diagnosis, and reviewed cases with late relapsed (after >5 years) neuroblastoma in the literature. The case presented with recurrent disease at the T7 vertebra after 11 years from the initial diagnosis. The patient received surgery, che motherapy, MIBG treatment, and antiGD2 combined with che motherapy, and had a further local recurrence in the paravertebral area of the re moved T7 vertebra after three years. The patient was operated, received anti-GD2 combined with che motherapy, and is still alive with no symptoms for 19 months after the last relapse.

Conclusion

There is not a well-established treatment regimen for the majority of these patients. MIBG treatment and antiGD2 combined with che motherapy may be promising options for relapsed/refractory neuroblastoma.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpr/10.2174/0115733963255648231024081333
2023-10-27
2024-12-24

  • From This Site

    /content/journals/cpr/10.2174/0115733963255648231024081333
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ColonN.C. ChungD.H. Neuroblastoma.Adv. Pediatr.201158129731110.1016/j.yapd.2011.03.01121736987
     [Google Scholar]
  2. RiesL.A.G. SmithM.A. GurneyJ.G. Cancer incidence and survival a mong children and adolescents: United States SEER program 1975–1995.Bethesda, MDNational Cancer Institute1999
     [Google Scholar]
  3. CohnS.L. PearsonA.D.J. LondonW.B. monclairT. AmbrosP.F. BrodeurG.M. FaldumA. HeroB. IeharaT. MachinD. mosseriV. Si monT. GaraventaA. CastelV. MatthayK.K. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG task force report.J. Clin. Oncol.200927228929710.1200/JCO.2008.16.678519047291
     [Google Scholar]
  4. DuBoisS.G. MacyM.E. HendersonT.O. High-risk and relapsed neuroblastoma: Toward more cures and better outcomes.Am. Soc. Clin. Oncol. Educ. Book2022424276878010.1200/EDBK_34978335522915
     [Google Scholar]
  5. ChungC BoterbergT LucasJ PanoffJ Valteau-CouanetD HeroB BagatellR Hill-KayserCE Neuroblastoma.Pediatr Blood Cancer.202168S2e28473
     [Google Scholar]
  6. LondonW.B. CastelV. monclairT. AmbrosP.F. PearsonA.D.J. CohnS.L. BertholdF. NakagawaraA. LadensteinR.L. IeharaT. MatthayK.K. Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group project.J. Clin. Oncol.201129243286329210.1200/JCO.2010.34.339221768459
     [Google Scholar]
  7. MarisJ.M. Recent advances in neuroblastoma.N. Engl. J. Med.2010362232202221110.1056/NEJMra080457720558371
     [Google Scholar]
  8. CotterillS.J. PearsonA.D.J. PritchardJ. KohlerJ.A. FootA.B.M. Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: A report from the European Neuroblastoma Study Group? Survey?Med. Pediatr. Oncol.200136123523810.1002/1096‑911X(20010101)36:1<235::AID‑MPO1057>3.0.CO;2‑N11464893
     [Google Scholar]
  9. WhittleS.B. SmithV. DohertyE. ZhaoS. McCartyS. ZageP.E. Overview and recent advances in the treatment of neuroblastoma.Expert Rev. Anticancer Ther.201717436938610.1080/14737140.2017.128523028142287
     [Google Scholar]
  10. MatthayK.K. MarisJ.M. SchleiermacherG. NakagawaraA. MackallC.L. DillerL. WeissW.A. Neuroblastoma.Nat. Rev. Dis. Primers2016211607810.1038/nrdp.2016.7827830764
     [Google Scholar]
  11. LauL. TaiD. WeitzmanS. GrantR. BaruchelS. MalkinD. Factors influencing survival in children with recurrent neuroblastoma.J. Pediatr. Hematol. Oncol.200426422723210.1097/00043426‑200404000‑0000315087949
     [Google Scholar]
  12. GaraventaA. ParodiS. De BernardiB. DauD. ManzittiC. ConteM. CasaleF. ViscardiE. BianchiM. D’AngeloP. ZanazzoG.A. LukschR. FavreC. TamburiniA. HauptR. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.Eur. J. Cancer200945162835284210.1016/j.ejca.2009.06.01019616426
     [Google Scholar]
  13. MorenoL. RubieH. VaroA. Le DeleyM.C. A morosoL. ChevanceA. GaraventaA. GambartM. BautistaF. Valteau-CouanetD. GeoergerB. VassalG. PaolettiX. PearsonA.D.J. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.Pediatr. Blood Cancer2017641253110.1002/pbc.2619227555472
     [Google Scholar]
  14. MorgensternD.A. BagatellR. CohnS.L. HogartyM.D. MarisJ.M. morenoL. ParkJ.R. PearsonA.D. SchleiermacherG. Valteau-CouanetD. LondonW.B. IrwinM.S. The challenge of defining “ultra-high-risk” neuroblastoma.Pediatr. Blood Cancer2019664e2755610.1002/pbc.2755630479064
     [Google Scholar]
  15. ChanG.C.F. ChanC.M. Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma.Bio molecules202212335810.3390/biom1203035835327550
     [Google Scholar]
  16. ModyR. NaranjoA. Van RynC. Randomised phase II trial of irinotecan/te mozolomide (I/T) with temsirolimus (TEM) or Dinutuximab (DIN) in children with refractory or relapsed neuroblastoma: A report from the children’s oncology group (COG).Lancet Oncol.201718794695710.1016/S1470‑2045(17)30355‑828549783
     [Google Scholar]
  17. LadensteinR. PötschgerU. Valteau-CouanetD. LukschR. CastelV. YanivI. LaureysG. BrockP. MichonJ.M. OwensC. TrahairT. ChanG.C.F. RuudE. SchroederH. Beck PopovicM. SchreierG. LoibnerH. AmbrosP. HolmesK. CastellaniM.R. GazeM.N. GaraventaA. PearsonA.D.J. LodeH.N. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): A multicentre, randomised, phase 3 trial.Lancet Oncol.201819121617162910.1016/S1470‑2045(18)30578‑330442501
     [Google Scholar]
  18. ModyR. YuA.L. NaranjoA. ZhangF.F. LondonW.B. ShulkinB.L. ParisiM.T. ServaesS.E.N. DiccianniM.B. HankJ.A. FelderM. BirstlerJ. SondelP.M. AsgharzadehS. Glade-BenderJ. KatzensteinH. MarisJ.M. ParkJ.R. BagatellR. Irinotecan, te mozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: A report from the Children’s Oncology Group.J. Clin. Oncol.202038192160216910.1200/JCO.20.0020332343642
     [Google Scholar]
  19. LadensteinR. PötschgerU. Valteau-CouanetD. LukschR. CastelV. AshS. LaureysG. BrockP. MichonJ.M. OwensC. TrahairT. Ruud Schroeder Beck-Popovic Schreier Loibner Ambros Holmes Castellani Gaze Garaventa Pearson Lode LodeH.N. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1).Cancers202012230910.3390/cancers1202030932013055
     [Google Scholar]
  20. OlgunN. CecenE. InceD. KizmazogluD. BaysalB. OnalA. OzdoganO. GuleryuzH. CetingozR. DemiralA. OlgunerM. CelikA. KamerS. OzerE. AltunZ. AktasS. Dinutuximab beta plus conventional che motherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.Front. Oncol.202212104144310.3389/fonc.2022.104144336620564
     [Google Scholar]
  21. Al-FarajE. MillarB.A. IrwinM.S. GuptaA. Isolated late CNS relapse in a young adult 10 years after initial treatment for neuroblastoma.J. Pediatr. Hematol. Oncol.2015371757710.1097/MPH.000000000000016324755834
     [Google Scholar]
  22. OkitaY. NaritaY. YoshidaA. MiyakitaY. OhnoM. SaioM. YoshimiN. ShibuiS. The late recurrence of ganglioneuroma 21 years after initial presentation with neuroblastoma.Pediatr. Hematol. Oncol.201229764765122966943
     [Google Scholar]
  23. OlgunN. AksoylarS. VaranA. VerginC. HazarV. AkiciF. DagdemirA. BuyukavciM. KebudiR. KurucuN. SevinirB. UnalE. VuralS. GulerE. ApakH. OnizH. KaradenizC. CanpolatC. AnakS. IlhanI. InceD. CecenE. Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group.J. Cancer Res. Ther.201713228429010.4103/0973‑1482.18320528643749
     [Google Scholar]
  24. KebudiR. AlkayaD.U. Epidemiology and survival of childhood cancer in Turkey.Pediatr. Blood Cancer2021682e2875410.1002/pbc.2875433034155
     [Google Scholar]
  25. EscobarM.A. GrosfeldJ.L. PowellR.L. WestK.W. SchererL.R.III FallonR.J. RescorlaF.J. Long-term outcomes in patients with stage IV neuroblastoma.J. Pediatr. Surg.200641237738110.1016/j.jpedsurg.2005.11.03216481255
     [Google Scholar]
  26. PflugerT. SchmiedC. PornU. LeinsingerG. VollmarC. DreselS. SchmidI. HahnK. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma.AJR Am. J. Roentgenol.200318141115112410.2214/ajr.181.4.181111514500242
     [Google Scholar]
  27. BleekerG. TytgatG.A.M. AdamJ.A. CaronH.N. KremerL.C.M. HooftL. van DalenE.C. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.Cochrane Libr.201520159CD00926310.1002/14651858.CD009263.pub226417712
     [Google Scholar]
  28. GutenbergA. SchultenH.J. GunawanB. LudwigH.C. BrückW. LarsenJ. RohdeV. CNS tu mor 22 years after spinal neuroblastoma IV: Diagnostic dilemma between recurrence and secondary malignancy.Pediatr. Neurosurg.2009451616810.1159/00020490619258732
     [Google Scholar]
  29. KushnerB.H. KramerK. CheungN.K.V. Chronic neuroblastoma.Cancer20029561366137510.1002/cncr.1080012216106
     [Google Scholar]
  30. CerveraA. KingstonJ.E. MalpasJ.S. Late recurrence of neuroblastoma: A report of five cases and review of the literature.Pediatr. Hematol. Oncol.19907431132210.3109/088800190090334082268531
     [Google Scholar]
  31. HataY. SasakiF. NaitoH. TakahashiH. NamienoT. UchinoJ. Late recurrence in neuroblastoma.J. Pediatr. Surg.199126121417141910.1016/0022‑3468(91)91053‑21765927
     [Google Scholar]
  32. PierceS.T. Long-term survival in refractory recurrent neuroblastoma.J. Pediatr. Hematol. Oncol.199618220220510.1097/00043426‑199605000‑000238846140
     [Google Scholar]
  33. KatoK. IshikawaK. ToyodaY. KigasawaH. AidaN. NishiT. KusafukaT. HaraJ. IjiriR. TanakaY. Late recurrence of neuroblastoma stage 4S with unusual clinicopathologic findings.J. Pediatr. Surg.200136695395510.1053/jpsu.2001.2400211381437
     [Google Scholar]
  34. BoulterA.C. WattT. An unusual case of late recurrence of ms neuroblastoma in a young adult.J. Pediatr. Hematol. Oncol.2023451e124e12510.1097/MPH.000000000000258436598966
     [Google Scholar]
  35. HaghiriS. FayechC. MansouriI. DufourC. PasqualiniC. BolleS. RivolletS. DumasA. BoumarafA. BelhoutA. JournyN. SouchardV. Vu-BezinG. VeresC. HaddyN. De VathaireF. Valteau-CouanetD. FresneauB. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose che motherapy and stem cell transplantation rescue.Bone Marrow Transplant.20215681984199710.1038/s41409‑021‑01258‑133824435
     [Google Scholar]
/content/journals/cpr/10.2174/0115733963255648231024081333
Loading
Late Relapse in Neuroblastoma: Case Report and Review of the Literature
Curr Pediatr Rev 21, 186 (2025); https://doi.org/10.2174/0115733963255648231024081333
/content/journals/cpr/10.2174/0115733963255648231024081333
/content/journals/cpr/10.2174/0115733963255648231024081333
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): dinutuximab; ganglioneuroblastoma; ganglioneuroma; late relapse; MIBG; Neuroblastoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test